Zavedos Adverse Reactions

The following adverse events (not listed in order of frequency) have been reported in association with idarubicin hydrochloride therapy (see Precautions): Infections and infestations: infection, sepsis/septicemia.
Neoplasms benign, malignant and unspecified: secondary leukemias (acute myeloid leukemia and myelodysplastic syndrome).
Blood and lymphatic system disorders: anemia leukopenia, neutropenia, thrombocytopenia.
Immune system disorders: anaphylaxis.
Metabolism and nutrition disorders: anorexia, dehydration, hyperuricemia.
Cardiac disorders: atrioventricular block, bundle branch block, congestive heart failure, myocarditis, pericarditis, sinus tachycardia, tachyarrhythmias.
Vascular disorders: hemorrhage, hot flashes, phlebitis, shock, thrombophlebitis, thromboembolism.
Gastrointestinal disorders: abdominal pain or burning sensation, colitis (including severe enterocolitis/neutropenic enterocolitis with perforation), diarrhea, erosions/ulceration, esophagitis, gastrointestinal tract bleeding, mucositis/stomatitis, nausea, vomiting.
Skin and subcutaneous tissue disorders: acral erythema, alopecia, hypersensitivity of irradiated skin ('radiation recall reaction'), local toxicity, rash/itch, skin changes, skin and nail hyperpigmentation, urticaria.
Renal and urinary disorders: red color to the urine for 1-2 days after administration.
General disorders and administration site conditions: fever.
Investigations: asymptomatic reductions in left ventricular ejection fraction, ECG abnormalities, elevation of liver enzymes and bilirubin.